Where the category stands in May 2026 — what's available, who to trust, what costs what. 22-min read, medically reviewed.
Read the guideAn independent overview of the compounded-GLP-1 telehealth market and the providers we cover — market size, what the FDA changed, and an honest read on each.
View the provider overviewOverview & reviewsPrimers for newcomers and deep dives for the curious. The foundation articles are published; more are in the pipeline.
View all Learn articlesWhat compounded and branded semaglutide and tirzepatide actually cost, from each provider's own published pricing.
How big the compounded-GLP-1 telehealth market is, what the FDA changed, and the providers we cover — with the honest read on each. Independent: placement and scoring are never for sale.
Editorial independence. PeptideWellness does not take payment from providers in exchange for placement or scoring. Provider coverage is determined by editorial judgment alone. Prices and head-to-head verdicts live in each provider's full review and in the comparison pages — not on this overview.
The honest answer is that GLP-1 and broader obesity medicines are the only segment we can size from primary sources — public-company filings and IQVIA's commercial-intelligence reports. The wider "peptide therapeutics" market (insulin, oncology peptides, anti-infectives) is covered by commercial market-research firms whose estimates diverge by more than 2× across the same year; we treat those as a noisy range, not authority.
What the primary sources show. IQVIA's ForecastLink projects the global obesity-medicines market at about $66B in 2025, rising to $92B in 2026 and $105–200B by 2027+. The engine is the GLP-1 / GIP class. Eli Lilly's Mounjaro + Zepbound (tirzepatide) together generated $36.5B in 2025 — Mounjaro $23.0B and Zepbound $13.5B for the full year, per Lilly's Q4 2025 financial results; IQVIA reports the pair surpassed Merck's Keytruda as the world's best-selling medicine. Novo Nordisk's semaglutide products (Ozempic + Wegovy) added roughly $25B USD in 2024 — Ozempic ~$17B and Wegovy ~$8B, with Wegovy revenue roughly doubling year-over-year as obesity uptake accelerated.
The telehealth / compounded niche is what PeptideWellness actually covers — narrower, newer, and not cleanly sized by the big reports. The signals of its scale: Hims & Hers alone projected $2.7–2.9B revenue for 2026 in its Q4 2025 SEC filing; a peer-reviewed AJMC analysis of a US commercial claims database (28.2M enrollees in 2018, 23.0M in 2023) found GLP-1 RA users grew from 745 per 100,000 enrollees in 2018 to 3,572 per 100,000 in 2023 — and within that pool, the share without a diabetes diagnosis roughly tripled, from 11% to 34%, as off-label weight-loss use accelerated; and IQVIA tracks compounded GLP-1 as a distinct "non-traditional channel" reshaping pharma distribution.
Scope caveat, stated plainly. Even the primary sources above are pharma-centric — organised around clinical indications. They map well onto GLP-1 weight loss and poorly onto our other categories — recovery, longevity, cognitive, skin/hair. Most of those circulate as compounded or research-grade peptides outside the formal therapeutics market, so reliable top-down sizing for them barely exists. Demand there is real but under-measured.
For most of 2023–2024, "compounded semaglutide" was a shortage-era workaround that turned into a category. Telehealth brands built funnels around it, and prices fell fast. Then the legal basis moved out from under it.
The FDA delisted tirzepatide from its shortage list in December 2024 and semaglutide in February 2025. The 503A grace period ended 22 April 2025; the 503B grace period ended 22 May 2025. The agency has publicly flagged adverse-event reports tied to compounded versions — by 31 July 2025, external analyses of FAERS data counted 1,150+ events including 17 reported deaths, though FDA itself notes that compounded-pharmacy events are systematically under-reported (most state-licensed compounders are not required to file with FAERS). On 30 April 2026 the agency proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List permanently, with public comment open until 29 June 2026.
The practical effect: mass-compounding of sema/tirz no longer rests on a shortage justification. What remains is narrow, patient-specific 503A compounding; it's bulk 503B sema/tirz that loses its footing first. The branded drugs (Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda) remain the FDA-approved reference point that compounded versions are modeled on.
Providers have responded in three ways — and that response is the clearest way to read the market:
Worth flagging: legal status here is dynamic. Every provider page says so, and dates its claims.
The notes below describe the providers we cover qualitatively; prices and head-to-head verdicts are left to the individual reviews and comparisons.
Almost entirely cash-pay direct-to-consumer. Insurance involvement is limited across the category.
Breadth varies across three groups. TrimRx and Mochi are GLP-1-only. Hims, Ro, Henry Meds, and Maximus add some adjacent products (men's health, recovery, biohacking). TeleZenMD has the widest menu — recovery, longevity, sexual health, skin/hair, and hormones alongside GLP-1.
A premium DTC band (Hims, Ro, Henry Meds) sells brand polish, app experience, and pharmacy depth. A budget DTC band (TrimRx, Maximus, Mochi) competes on sticker price and on niche positioning — Maximus, for example, on microdose and stacking optionality. TeleZenMD doesn't sit cleanly in either tier: a multi-category model with a mid-market price band.
Most plans are month-to-month. Hims ties its headline rate to a six-month commitment. Annual or multi-month prepayment plans, where offered, buy the lowest monthly-equivalent rate in exchange for paying upfront.
Most of the set still offers compounded tirzepatide. Hims is the notable exit (discontinued late 2025 / early 2026). Regulation-sensitive — recheck after 29 June 2026.
Provider-by-provider market share or patient volume. The companies don't publish those numbers, and no independent tracker aggregates them at this level. We don't repeat figures we can't source.
Listed alphabetically — name, what kind of provider it is, how broad its menu is, and who it's best for. No prices, no rankings here; those live in each provider's full review and in the comparison pages.
| Provider | Breadth | Best for |
|---|---|---|
| Henry Meds › Budget DTC (compounded) | GLP-1 + phentermine + TRT + HRT + ED | Lowest-priced compounded GLP-1 ladder from a high-volume operator (12k+ Trustpilot reviews) |
| Hims › Premium DTC (public) | Branded GLP-1 + sexual + hair + mental + labs | Patients who want FDA-approved branded GLP-1 via manufacturer-direct programs, with a credentialed advisory board |
| Maximus › Premium DTC (men's hormone) | Testosterone (4 formats) + GLP-1 + peptides | Optimization-focused men committed to testosterone protocols with academic-urology advisors |
| Mochi Health › Budget DTC (compounded) | GLP-1 marketplace + skincare / hair / mental | Patients who want provider and pharmacy choice in a membership marketplace |
| Ro › Premium DTC (private) | Branded GLP-1 + sexual + hair + derm + fertility | Patients who want the broadest branded DTC menu with an insurance-check option |
| TeleZenMD › Multi-category DTC | Widest peptide menu in the set | Patients who want a system — breadth, behavioral program, named physicians |
| TrimRx › Budget DTC (compounded) | GLP-1 only (compounded sema + tirz) | Price-driven patients aware of the documented billing-complaint pattern |
Market sizing (§01) — primary sources we anchor on
Regulatory timeline (§02)
Provider descriptions (§§03–04) come from each provider's public site, accessed June 2026; specific URLs are listed inside each provider's full review.